Background: Esophageal cancer (EC) is the eighth most prevalent malignant tumor and the sixth leading cause of cancer mortality throughout the world. Despite the technical developments in diagnosis and treatment, the 5-year survival rate is still low. The etiology of EC remains poorly understood; multiple risk factors may be involved and account for the great variation in EC incidence in different geographic regions. Summary: Infection with carcinogenetic pathogens has been proposed as a risk factor for EC. This review explores the recent studies on the association of human papillomavirus (HPV), Epstein-Barr virus (EBV), Helicobacter pylori and esophageal bacterial biota with EC. Key Message: Among the above-mentioned pathogens, HPV most likely contributes to esophageal squamous cell carcinoma (ESCC) in high-risk populations. New techniques are being applied to studies on the role of infection in EC, which will inevitably bring novel ideas to the field in the near future. Practical Implications: Multiple meta-analyses support the finding of a higher HPV detection rate in regions associated with high risk for ESCC compared to low-risk areas. A potential role of HPV in the rise of esophageal adenocarcinoma (EAC) was proposed recently. However, further studies are required before a firm conclusion can be drawn. Less work has been done in studying the association between EBV and ESCC, and the results are quite controversial. H. pylori infection is found to be inversely related to EC, which is probably due to the reduced incidence of gastroesophageal reflux disease. Analysis of the esophageal bacterial biota revealed distinct clusters of bacteria in normal and diseased esophagi. A type II microbiome rich in Gram-negative bacteria potentially contributes to EAC by inducing chronic inflammation. Novel findings from such studies as these may benefit public health by justifying anti-infection measures to prevent EC.

Keywords:
Bacterial biota, Epstein-Barr virus, Esophageal cancer, Esophageal squamous cell carcinoma, Human papillomavirus
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2.
Edgren G, Adami HO, Weiderpass E, Nyren O: A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013;62:1406-1414.
3.
Shimizu Y, Tsukagoshi H, Fujita M, Hosokawa M, Kato M, Asaka M: Long-term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper. Gastrointest Endosc 2002;56:387-390.
4.
Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG, Kesler KA, Law S, Lerut TE, Reed CE, Salo JA, Scott WJ, Swisher SG, Watson TJ, Blackstone EH: Worldwide esophageal cancer collaboration. Dis Esophagus 2009;22:1-8.
5.
Siegel R, Naishadham D, Jemal A: Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 2012;62:283-298.
6.
Corley DA, Buffler PA: Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001;30:1415-1425.
7.
Castellsague X, Munoz N, De Stefani E, Victora CG, Castelletto R, Rolon PA, Quintana MJ: Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int J Cancer 1999;82:657-664.
8.
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M: Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-615.
9.
Syrjanen K, Pyrhonen S, Aukee S, Koskela E: Squamous cell papilloma of the esophagus: a tumour probably caused by human papilloma virus (HPV). Diagn Histopathol 1982;5:291-296.
10.
zur Hausen H: Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009;384:260-265.
11.
Mesri EA, Feitelson MA, Munger K: Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014;15:266-282.
12.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004;324:17-27.
13.
Van Doorslaer K, Tan Q, Xirasagar S, Bandaru S, Gopalan V, Mohamoud Y, Huyen Y, McBride AA: The Papillomavirus Episteme: a central resource for papillomavirus sequence data and analysis. Nucleic Acids Res 2013;41(database issue):D571-D578.
14.
Zheng ZM, Baker CC: Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006;11:2286-2302.
15.
Conway MJ, Meyers C: Replication and assembly of human papillomaviruses. J Dent Res 2009;88:307-317.
16.
Chiang CM, Ustav M, Stenlund A, Ho TF, Broker TR, Chow LT: Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc Natl Acad Sci USA 1992;89:5799-5803.
17.
de Villiers EM, Gissmann L, zur Hausen H: Molecular cloning of viral DNA from human genital warts. J Virol 1981;40:932-935.
18.
Gissmann L, zur Hausen H: Partial characterization of viral DNA from human genital warts (condylomata acuminata). Int J Cancer 1980;25:605-609.
19.
Castillo A, Koriyama C, Higashi M, Anwar M, Bukhari MH, Carrascal E, Mancilla L, Okumura H, Matsumoto M, Sugihara K, Natsugoe S, Eizuru Y, Akiba S: Human papillomavirus in upper digestive tract tumors from three countries. World J Gastroenterol 2011;17:5295-5304.
20.
Durst M, Croce CM, Gissmann L, Schwarz E, Huebner K: Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci USA 1987;84:1070-1074.
21.
Pett MR, Alazawi WO, Roberts I, Dowen S, Smith DI, Stanley MA, Coleman N: Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res 2004;64:1359-1368.
22.
McLaughlin-Drubin ME, Meyers J, Munger K: Cancer associated human papillomaviruses. Curr Opin Virol 2012;2:459-466.
23.
Moody CA, Laimins LA: Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10:550-560.
24.
Syrjanen KJ: Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas. Arch Geschwulstforsch 1982;52:283-292.
25.
Syrjanen KJ: HPV infections and oesophageal cancer. J Clin Pathol 2002;55:721-728.
26.
Liu F, Guo F, Zhou Y, He Z, Tian X, Guo C, Ning T, Pan Y, Cai H, Ke Y: The Anyang Esophageal Cancer Cohort Study: study design, implementation of fieldwork, and use of computer-aided survey system. PLoS One 2012;7:e31602.
27.
Xu CL, Qian XL, Zhou XS, Zhao QZ, Li YC: Expression of HPV16-E6 and E7 oncoproteins in squamous cell carcinoma tissues of esophageal cancer and non-cancer tissues (in Chinese). Ai Zheng 2004;23:165-168.
28.
Antunes LC, Prolla JC, de Barros Lopes A, da Rocha MP, Fagundes RB: No evidence of HPV DNA in esophageal squamous cell carcinoma in a population of Southern Brazil. World J Gastroenterol 2013;19:6598-6603.
29.
Liyanage SS, Segelov E, Malik A, Garland SM, Tabrizi SN, Cummins E, Seale H, Rahman B, Moa A, Barbour AP, Crowe PJ, MacIntyre CR: A case-control study of the role of human papillomavirus in oesophageal squamous cell carcinoma in Australia. J Oncol 2014;2014:236482.
30.
Wang X, Tian X, Liu F, Zhao Y, Sun M, Chen D, Lu C, Wang Z, Shi X, Zhang Q, Zhang D, Shen Z, Li F, Harris CC, Cai H, Ke Y: Detection of HPV DNA in esophageal cancer specimens from different regions and ethnic groups: a descriptive study. BMC Cancer 2010;10:19.
31.
He Z, Xu Z, Hang D, Guo F, Abliz A, Weiss NS, Xi L, Liu F, Ning T, Pan Y, Guo C, Liang Y, Lu C, Zhang L, Cai H, Ke Y: Anti-HPV-E7 seropositivity and risk of esophageal squamous cell carcinoma in a high-risk population in China. Carcinogenesis 2014;35:816-821.
32.
Chen WG, Yang CM, Xu LH, Zhang N, Liu XY, Ma YG, Huo XL, Han YS, Tian DA, Zheng Y: Gene chip technology used in the detection of HPV infection in esophageal cancer of Kazakh Chinese in Xinjiang Province. J Huazhong Univ Sci Technolog Med Sci 2014;34:343-347.
33.
Yang J, Wu H, Wei S, Xiong H, Fu X, Qi Z, Jiang Q, Li W, Hu G, Yuan X, Liao Z: HPV seropositivity joints with susceptibility loci identified in Glassy at apoptosis associated genes to increase the risk of esophageal squamous cell carcinoma (ESCC). BMC Cancer 2014;14:501.
34.
Gao H, Wang L, Cui S, Wang M: Combination of meta-analysis and graph clustering to identify prognostic markers of ESCC. Genet Mol Biol 2012;35:530-537.
35.
Hardefeldt HA, Cox MR, Eslick GD: Association between human papillomavirus (HPV) and oesophageal squamous cell carcinoma: a meta-analysis. Epidemiol Infect 2014;142:1119-1137.
36.
Li X, Gao C, Yang Y, Zhou F, Li M, Jin Q, Gao L: Systematic review with meta-analysis: the association between human papillomavirus infection and oesophageal cancer. Aliment Pharmacol Ther 2014;39:270-281.
37.
Cao F, Han H, Zhang F, Wang B, Ma W, Wang Y, Sun G, Shi M, Ren Y, Cheng Y: HPV infection in esophageal squamous cell carcinoma and its relationship to the prognosis of patients in northern China. ScientificWorldJournal 2014;2014:804738.
38.
Herbster S, Ferraro CT, Koff NK, Rossini A, Kruel CD, Andreollo NA, Rapozo DC, Blanco TC, Faria PA, Santos PT, Albano RM, Simao Tde A, Pinto LF: HPV infection in Brazilian patients with esophageal squamous cell carcinoma: interpopulational differences, lack of correlation with surrogate markers and clinicopathological parameters. Cancer Lett 2012;326:52-58.
39.
Koh JS, Lee SS, Baek HJ, Kim YI: No association of high-risk human papillomavirus with esophageal squamous cell carcinomas among Koreans, as determined by polymerase chain reaction. Dis Esophagus 2008;21:114-117.
40.
Lofdahl HE, Du J, Nasman A, Andersson E, Rubio CA, Lu Y, Ramqvist T, Dalianis T, Lagergren J, Dahlstrand H: Prevalence of human papillomavirus (HPV) in oesophageal squamous cell carcinoma in relation to anatomical site of the tumour. PLoS One 2012;7:e46538.
41.
Sitas F, Egger S, Urban MI, Taylor PR, Abnet CC, Boffetta P, O'Connell DL, Whiteman DC, Brennan P, Malekzadeh R, Pawlita M, Dawsey SM, Waterboer T; InterSCOPE Collaboration: InterSCOPE study: associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst 2012;104:147-158.
42.
Rajendra S, Wang B, Snow ET, Sharma P, Pavey D, Merrett N, Ball MJ, Brain T, Fernando R, Robertson IK: Transcriptionally active human papillomavirus is strongly associated with Barrett's dysplasia and esophageal adenocarcinoma. Am J Gastroenterol 2013;108:1082-1093.
43.
Al-Haddad S, El-Zimaity H, Hafezi-Bakhtiari S, Rajendra S, Streutker CJ, Vajpeyi R, Wang B: Infection and esophageal cancer. Ann NY Acad Sci 2014;1325:187-196.
44.
Wiedorn KH, Kuhl H, Galle J, Caselitz J, Vollmer E: Comparison of in-situ hybridization, direct and indirect in-situ PCR as well as tyramide signal amplification for the detection of HPV. Histochem Cell Biol 1999;111:89-95.
45.
Yong F, Xudong N, Lijie T: Human papillomavirus types 16 and 18 in esophagus squamous cell carcinoma: a meta-analysis. Ann Epidemiol 2013;23:726-734.
46.
Liyanage SS, Rahman B, Ridda I, Newall AT, Tabrizi SN, Garland SM, Segelov E, Seale H, Crowe PJ, Moa A, MacIntyre CR: The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One 2013;8:e69238.
47.
Syrjanen K, Syrjanen S: Detection of human papillomavirus in sinonasal carcinoma: systematic review and meta-analysis. Hum Pathol 2013;44:983-991.
48.
Petrick JL, Wyss AB, Butler AM, Cummings C, Sun X, Poole C, Smith JS, Olshan AF: Prevalence of human papillomavirus among oesophageal squamous cell carcinoma cases: systematic review and meta-analysis. Br J Cancer 2014;110:2369-2377.
49.
Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-768.
50.
Thompson MP, Kurzrock R: Epstein-Barr virus and cancer. Clin Cancer Res 2004;10:803-821.
51.
Mizobuchi S, Sakamoto H, Tachimori Y, Kato H, Watanabe H, Terada M: Absence of human papillomavirus-16 and -18 DNA and Epstein-Barr virus DNA in esophageal squamous cell carcinoma. Jpn J Clin Oncol 1997;27:1-5.
52.
Yanai H, Hirano A, Matsusaki K, Kawano T, Miura O, Yoshida T, Okita K, Shimizu N: Epstein-Barr virus association is rare in esophageal squamous cell carcinoma. Int J Gastrointest Cancer 2003;33:165-170.
53.
Sunpaweravong S, Mitarnun W, Puttawibul P: Absence of Epstein-Barr virus in esophageal squamous cell carcinoma. Dis Esophagus 2005;18:398-399.
54.
Wang J, Noffsinger A, Stemmermann G, Fenoglio-Preiser C: Esophageal squamous cell carcinomas arising in patients from a high-risk area of North China lack an association with Epstein-Barr virus. Cancer Epidemiol Biomarkers Prev 1999;8:1111-1114.
55.
Wang LS, Chow KC, Wu YC, Li WY, Huang MH: Detection of Epstein-Barr virus in esophageal squamous cell carcinoma in Taiwan. Am J Gastroenterol 1999;94:2834-2839.
56.
Jenkins TD, Nakagawa H, Rustgi AK: The association of Epstein-Barr virus DNA with esophageal squamous cell carcinoma. Oncogene 1996;13:1809-1813.
57.
Awerkiew S, Bollschweiler E, Metzger R, Schneider PM, Holscher AH, Pfister H: Esophageal cancer in Germany is associated with Epstein-Barr-virus but not with papillomaviruses. Med Microbiol Immunol 2003;192:137-140.
58.
Wu MY, Wu XY, Zhuang CX: Detection of HSV and EBV in esophageal carcinomas from a high-incidence area in Shantou China. Dis Esophagus 2005;18:46-50.
59.
Peek RM Jr, Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
60.
de Korwin JD: Epidemiology of Helicobacter pylori infection and gastric cancer (in French). Rev Prat 2014;64:189-193.
61.
Cheng HC, Wang JD, Chen WY, Chen CW, Chang SC, Sheu BS: Helicobacter pylori test-and-treat program can be cost-effective to prevent gastric cancer in Taiwanese adults: referred to the nationwide reimbursement database. Helicobacter 2015;20:114-124.
62.
Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.
63.
Koike T, Ohara S, Sekine H, Iijima K, Kato K, Shimosegawa T, Toyota T: Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999;94:3468-3472.
64.
Tummuru MKR, Sharma SA, Blaser MJ: Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Mol Microbiol 1995;18:867-876.
65.
Glocker E, Lange C, Covacci A, Bereswill S, Kist M, Pahl HL: Proteins encoded by the cag pathogenicity island of Helicobacter pylori are required for NF-kappaB activation. Infect Immun 1998;66:2346-2348.
66.
Hatakeyama M, Brzozowski T: Pathogenesis of Helicobacter pylori infection. Helicobacter 2006;11(suppl 1): 14-20.
67.
Cunningham-Rundles S, Ahrn S, Abuav-Nussbaum R, Dnistrian A: Development of immunocompetence: role of micronutrients and microorganisms. Nutr Rev 2002;60(5 Pt 2):S68-S72.
68.
Wang ZK, Yang YS: Upper gastrointestinal microbiota and digestive diseases. World J Gastroenterol 2013;19:1541-1550.
69.
Hugenholtz P, Goebel BM, Pace NR: Impact of culture-independent studies on the emerging phylogenetic view of bacterial diversity. J Bacteriol 1998;180:4765-4774.
70.
Pei Z, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ: Bacterial biota in the human distal esophagus. Proc Natl Acad Sci USA 2004;101:4250-4255.
71.
Liu N, Ando T, Ishiguro K, Maeda O, Watanabe O, Funasaka K, Nakamura M, Miyahara R, Ohmiya N, Goto H: Characterization of bacterial biota in the distal esophagus of Japanese patients with reflux esophagitis and Barrett's esophagus. BMC Infect Dis 2013;13:130.
72.
Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z: Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 2009;137:588-597.
73.
Fan YP, Chakder S, Gao F, Rattan S: Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction. Am J Physiol Gastrointest Liver Physiol 2001;280:G32-G42.
74.
Houghton J, Korah RM, Condon MR, Kim KH: Apoptosis in Helicobacter pylori associated gastric and duodenal ulcer disease is mediated via the Fas antigen pathway. Dig Dis Sci 1999;44:465-478.
75.
El-Omar EM, Carrington M, Chow WH, McColl KEL, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
76.
Hollingsworth MA, Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60.
77.
Dohrman A, Miyata S, Gallup M, Li JD, Chapelin C, Coste A, Escudier E, Nadel J, Basbaum C: Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gram-negative bacteria. Biochim Biophys Acta 1998;1406:251-259.
78.
Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K, Augenlicht L: Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002;295:1726-1729.
79.
Komatsu M, Jepson S, Arango ME, Carothers Carraway CA, Carraway KL: Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene 2001;20:461-470.
80.
Glickman JN, Blount PL, Sanchez CA, Cowan DS, Wongsurawat VJ, Reid B, Odze RD: Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus. Hum Pathol 2006;37:1304-1315.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.